Cost assessment of health interventions and diseases
Open accessThe DOI matches its Crossref record; 21 of the 23 references it cites were found in a registry or an index.
Abstract
Health resource use and identification of related costs are two essential steps in health economics assessment. The elicited costs will be balanced with health outcome improvement and enable the comparison of different diagnostic procedures or therapeutic strategies from a health economic point of view. The cost typology can be disentangled in three main components, that is, direct cost related to health resource use, indirect costs related to productivity loss and sometimes intangible costs (costs related to pain and suffering). These costs can be elicited from different perspectives depending on the general aim of the assessment: payer, societal perspective or patient perspective. Practically, the first step corresponds to the quantification of health resource use, that is, number of consultations, biological or imaging workups, hospitalisation, dispensed medication units or days on sick leave. It can be done by specific self-questionnaires or by access to insurance health databases. The second step is then to value each health resource use item, based on available public databases—either produced by insurance entities or statistics institute—providing the unit costs for each item. Importantly, substantial variability does exist in the costing exercise, requiring accepting a certain uncertainty around cost estimates. This can be taken into account by sensitivity analyses, which capture in what extent measurement error can impact cost assessment, depending on different hypotheses or assumptions. One essential element of health economic assessment is the identification of costs incurred by or associated with a specific health condition for a study on the economic burden of a disease—cost-of-illness study—or with a given diagnostic or therapeutic intervention in the context of health technology assessment in which these costs are compared with the alternative reference strategy—cost-effectiveness study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In ophthalmology, as in other disease areas, the research reflects three main categories of costs, including direct (medical and non-medical), indirect and intangible costs [22, 27–29].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experts have recognized the importance of adopting a standardized approach when quantifying costs, which ensures adequate comparisons across studies, especially in the case of systematic reviews where the fullness of incurred costs (including direct, indirect and intangible) pertaining to a particular disease area need to be reflected [22, 28, 29].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Measuring Worker Productivity: Frameworks and Measures
Beaton, D., Bombardier, C., Escorpizo, R. S., Zhang, W., Lacaille, D. V., Boonen, A. E. R. C. H., Osborne, R. H., Anis, A. H., STRAND, C. V., & Tugwell, P. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090366 · Cited by 180 · cited 1×
“7 They are rather straightforward and are mainly limited by potential memory biases when the questionnaire addresses long period of time (as for health consumption data).”
Self-citationWorker productivity outcome measures in arthritis.
Escorpizo, R. S., Bombardier, C., Boonen, A. E. R. C. H., Hazes, J. M. W., Lacaille, D. V., Strand, V., & Beaton, D. (2007) · PubMed · Cited by 149
Self-citationClarke, A. E., Zowall, H., Levinton, C. M., Assimakopoulos, H., Sibley, J. T., Haga, M., Shiroky, J. B., Neville, C., Lubeck, D. P., Grover, S. A., et al. (1997) · PubMed · Cited by 126
Merkesdal, S., Ruof, J., Sch�ffski, O., Bernitt, K., Zeidler, H., & Mau, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<528::aid-anr100>3.0.co;2-u · Cited by 120
Merkesdal, S., Ruof, J., Schöffski, O., Bernitt, K., Zeidler, H. K., & Mau, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<528::aid-anr100>3.3.co;2-l · Cited by 107
Clarke, A. E., Esdaile, J. M., Bloch, D. A., Lacaille, D., Danoff, D. S., & Fries, J. F. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361109 · Cited by 92
Tang, K., Escorpizo, R. S., Beaton, D., Bombardier, C., Lacaille, D. V., Zhang, W., Anis, A. H., Boonen, A. E. R. C. H., Verstappen, S. M. M., Buchbinder, R., et al. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110405 · Cited by 66
Self-citationBeaton, D., Dyer, S., Boonen, A. E. R. C. H., Verstappen, S. M. M., Escorpizo, R. S., Lacaille, D. V., Bosworth, A., Gignac, M. A. M., Leong, A. L., Purcaru, O., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141077 · Cited by 61 · cited 1×
“15 – 17 This can then be converted in lost hours or additional hours to perform to achieve the same task (table 2).”
Self-citationDevelopment of a matrix of cost domains in economic evaluation of rheumatoid arthritis.
Merkesdal, S., Ruof, J., Huelsemann, J. L., Schoeffski, O., Maetzel, A., Mau, W., & Zeidler, H. K. (2001) · PubMed · Cited by 56
Cited by
Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2022.2157596 · Cited by 57
“Intangible costs impact both patient and caregivers, and are a conceptual measure of the cost of pain and suffering 21 .”
BackgroundFajarini, M., Setiawan, A., Sung, C., Chen, R., Liu, D., Lee, C., Niu, S., & Chou, K. (2024) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2024.104953 · Cited by 56
Chen, S., Mao, Y., & Chen, G. (2022) · Endocrine · doi:10.1007/s12020-022-02991-3 · Cited by 27
“For society, cost types can be broken down into three main components: direct costs associated with using health resources, indirect costs related to lost productivity, and sometimes intangible costs (cost associated with pain) [27]; reducing costs leads to better allocation of resources.”
BackgroundAdanu, K. K., Bansah, E. C., Adedia, D., & Aikins, M. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000268 · Cited by 27
“[13], direct health services costs are primarily medical and non-medical costs.”
BackgroundExpanding the Catalog of Patient and Caregiver Out-of-Pocket Costs: A Systematic Literature Review
Schmidt, T. A., Juday, C., Patel, P., Karmarkar, T. D., Smith-Howell, E. R., & Fendrick, A. M. (2023) · Population Health Management · doi:10.1089/pop.2023.0238 · Cited by 24
Metadata
- Authors
- Fautrel, B., Boonen, A., de Wit, M., Grimm, S., Joore, M., & Guillemin, F.
- Affiliations
- Inserm (FR)
- Maastricht University Medical Centre (NL)
- Patient Research Partner, EULAR, Zaltbommel, Netherlands
- EA 4360 APEMAC, School of Public Health, Nancy, France
- Corresponding author
- Fautrel, Bruno
- Venue
- RMD Open
- Publisher
- BMJ
- Published
- 2020-11
- Volume
- 6
- Issue
- 3
- Pages
- e001287
- ISSN
- 2056-5933 (ISSN-L)
- PMC
- PMC7856133
- OpenAlex
- W3097229587
- Cited by
- 63
- References
- 23
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 14 · 2023: 7 · 2022: 4 · 2021: 1 · 2020: 2
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- RMD Open (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen
- Celgene
- Celltrion
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
- Physical Sciences › Engineering › Building and Construction › Life Cycle Costing Analysis
- Keywords
- cost evaluation, health care utilization, direct costs, indirect costs, productivity loss, intangible costs, cost database, sensitivity analysis, economic burden of disease, economic burden, health technology assessment, cost-effectiveness
- MeSH terms
- Cost-Benefit Analysis, Hospitalization, Humans, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost assessment of health interventions and diseases. https://app.cochat.ai/papers/10.1136/rmdopen-2020-001287
- The paper
- Fautrel, B., Boonen, A., de Wit, M., Grimm, S., Joore, M., & Guillemin, F. (2020). Cost assessment of health interventions and diseases. RMD Open. https://doi.org/10.1136/rmdopen-2020-001287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

